D&M Company Holds Study Session and Shares Materials on the FY2026 Medical Fee Revision – PR TIMES

News Highlights

D&M Company conducted a study session and shared materials in preparation for the FY2026 medical fee revision. This initiative highlights the importance of mid-to-long-term management and business succession strategies in anticipation of the revision cycle. Points such as maintaining facility standards through economies of scale, dispersing the burden of capital investment, and utilizing tax schemes with an eye toward transitioning to specific or social medical corporations have also emerged.

M&A Medical Editorial Department’s Perspective

The study session on the FY2026 medical fee revision by D&M Company goes beyond mere information sharing, concretely suggesting the integration of business succession and management strategies faced by medical institutions. In particular, mid-to-long-term strategies that consider the revision cycle are extremely important when considering M&A. For example, maintaining facility standards and dispersing capital investment burdens through group formation enables investments that would be difficult for a single entity, leading to the strengthening of the management base. Furthermore, utilizing tax schemes with a view to transitioning to specific or social medical corporations can not only reduce tax burdens at the time of succession but also contribute to the maintenance and development of the corporate status, making it increasingly important in M&A brokerage.

Points Indicated by This News

• The need for early preparation for the FY2026 medical fee revision and mid-to-long-term management and succession strategies in anticipation of it.
• The importance of economies of scale through group formation (maintaining facility standards and dispersing capital investment burdens).
• Consideration of utilizing tax schemes with a view to transitioning to specific or social medical corporations.
• The impact of medical fee revisions on the timing and scheme selection for business succession.

Practical Questions Arising from This News

• What specific revision items and impacts were included in the materials shared during this study session?
• What size and specialty of medical institutions was D&M Company targeting for this study session?
• Can you provide more detailed information on the specific merits and demerits of group formation and corporate status transition in anticipation of the revision?

If You Feel “Should I Consult Too?”

The trends of the FY2026 medical fee revision will have a significant impact on future management strategies and business succession plans. In particular, considering the maintenance of facility standards that are difficult to maintain alone, and the future burden of capital investment, strengthening the management base through group formation or transitioning corporate status by leveraging tax incentives can be a viable option for business succession. It will likely serve as an opportunity to consider whether it is time to consult with M&A and business succession experts, by comparing your institution’s management status and future plans.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics as a certified M&A support institution by the Small and Medium Enterprise Agency, with a complete success fee system. We handle consultations with strict confidentiality. Free consultation here